These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes. Bose G; Healy BC; Saxena S; Saleh F; Paul A; Barro C; Lokhande HA; Polgar-Turcsanyi M; Anderson M; Glanz BI; Guttmann CRG; Bakshi R; Weiner HL; Chitnis T Mult Scler Relat Disord; 2023 Jun; 74():104695. PubMed ID: 37060852 [TBL] [Abstract][Full Text] [Related]
10. Serum neurofilament light is a sensitive biomarker that reflects grey matter volume in Japanese patients with multiple sclerosis. Fujimori J; Nakashima I J Neurol Sci; 2021 Aug; 427():117528. PubMed ID: 34098375 [TBL] [Abstract][Full Text] [Related]
11. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. Bittner S; Steffen F; Uphaus T; Muthuraman M; Fleischer V; Salmen A; Luessi F; Berthele A; Klotz L; Meuth SG; Bayas A; Paul F; Hartung HP; Linker R; Heesen C; Stangel M; Wildemann B; Then Bergh F; Tackenberg B; Kuempfel T; Weber F; Zettl UK; Ziemann U; Tumani H; Groppa S; Mühlau M; Lukas C; Hemmer B; Wiendl H; Gold R; Zipp F; EBioMedicine; 2020 Jun; 56():102807. PubMed ID: 32460167 [TBL] [Abstract][Full Text] [Related]
12. Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis. Bsteh G; Berek K; Hegen H; Teuchner B; Buchmann A; Voortman MM; Auer M; Wurth S; Zinganell A; Di Pauli F; Deisenhammer F; Khalil M; Berger T Mult Scler; 2020 Nov; 26(13):1682-1690. PubMed ID: 31668116 [TBL] [Abstract][Full Text] [Related]
13. Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis. Loonstra FC; de Ruiter LRJ; Koel-Simmelink MJA; Schoonheim MM; Strijbis EMM; Moraal B; Barkhof F; Uitdehaag BMJ; Teunissen C; Killestein J Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36543540 [TBL] [Abstract][Full Text] [Related]
14. Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis. Sainz-Amo R; Rodero Romero A; Monreal E; Chico García JL; Fernández Velasco JI; Villarrubia N; Veiga González JL; Sainz de la Maza S; Rodríguez Jorge F; Masjuan J; Costa-Frossard L; Villar LM Front Immunol; 2024; 15():1454474. PubMed ID: 39224593 [TBL] [Abstract][Full Text] [Related]
15. Changes in serum neurofilament light chain levels following narrowband ultraviolet B phototherapy in clinically isolated syndrome. Fabis-Pedrini MJ; Kuhle J; Roberts KMA; Trend S; Jones AP; Maceski A; Carroll WM; Lucas RM; Mastaglia FL; Hart PH; Kermode AG Brain Behav; 2022 Feb; 12(2):e2494. PubMed ID: 35084124 [TBL] [Abstract][Full Text] [Related]
16. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. Meier S; Willemse EAJ; Schaedelin S; Oechtering J; Lorscheider J; Melie-Garcia L; Cagol A; Barakovic M; Galbusera R; Subramaniam S; Barro C; Abdelhak A; Thebault S; Achtnichts L; Lalive P; Müller S; Pot C; Salmen A; Disanto G; Zecca C; D'Souza M; Orleth A; Khalil M; Buchmann A; Du Pasquier R; Yaldizli Ö; Derfuss T; Berger K; Hermesdorf M; Wiendl H; Piehl F; Battaglini M; Fischer U; Kappos L; Gobbi C; Granziera C; Bridel C; Leppert D; Maleska Maceski A; Benkert P; Kuhle J JAMA Neurol; 2023 Mar; 80(3):287-297. PubMed ID: 36745446 [TBL] [Abstract][Full Text] [Related]
17. Association of serum neurofilament light with microglial activation in multiple sclerosis. Saraste M; Matilainen M; Vuorimaa A; Laaksonen S; Sucksdorff M; Leppert D; Kuhle J; Airas L J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):698-706. PubMed ID: 37130728 [TBL] [Abstract][Full Text] [Related]
18. sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients. Valentino P; Malucchi S; Martire S; Bava CI; Capobianco MA; Bertolotto A Mult Scler Relat Disord; 2022 Nov; 67():104176. PubMed ID: 36126541 [TBL] [Abstract][Full Text] [Related]
19. Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis. Hyun JW; Kim Y; Kim G; Kim SH; Kim HJ Mult Scler; 2020 May; 26(6):659-667. PubMed ID: 30912689 [TBL] [Abstract][Full Text] [Related]
20. Vitamin D supplementation and serum neurofilament light chain in interferon-beta-1b-treated MS patients. Hänninen K; Jääskeläinen O; Herukka SK; Soilu-Hänninen M Brain Behav; 2020 Sep; 10(9):e01772. PubMed ID: 32705821 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]